AOBiome, a brand that specialises in products for inflammatory skin conditions, has announced the start of a clinical trial that it hopes will result in a tangible cure for acne sufferers.
The Phase 2 clinical trial is the first to test the potential of live bacteria to treat acne. AOBiome is working with a therapeutic product candidate (B244) based on its proprietary ammonia oxidizing bacteria (AOB) for the treatment of mild to moderate Acne vulgaris.
Chief Medical Officer Larry Weiss, who has been working on the trial, told Cosmetics Business: “The clinical trial is designed to follow FDA guidances to determine that our live topical application of AOB are a safe, effective treatment for acne. These trials are structured to address questions including, safety, efficacy and dosing.”
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.
Subscribe now Already a subscriber? Sign in here.
